investigating bispecific antibodies in high-risk smoldering myeloma: the immunoprism platform study
Published 5 months ago • 170 plays • Length 1:23Download video MP4
Download video MP3
Similar videos
-
1:47
immunoprism: a platform study investigating bispecific antibodies in smoldering multiple myeloma
-
3:37
bispecific antibodies in multiple myeloma: their current role and the future
-
1:45
the advent of bispecific antibodies for multiple myeloma
-
2:22
outcomes and management of patients with r/r myeloma who progress on bispecific antibodies
-
7:05
developments in the use of bispecific antibodies in myeloma and challenges in this space
-
5:44
bispecific antibodies: early side effects
-
4:35
updated safety & efficacy data from manifest-2: pelabresib plus ruxolitinib for myelofibrosis
-
6:09
bispecific antibodies | high impact topic (hit)
-
1:19
sequencing bispecific antibodies and car-t therapy & the evolving role of bispecifics in myeloma
-
2:36
a cd38-targeting bispecific antibody in the treatment of r/r t-all
-
1:20
a comparison of bispecific antibodies emerging in multiple myeloma
-
1:15
safety & efficacy of bispecific antibodies in multiple myeloma: teclistamab & elranatamb
-
6:13
phase i study of forimtamig, a gprc5dxcd3 bispecific antibody, in r/r multiple myeloma
-
1:45
using the available repertoire of bispecific antibodies for treating multiple myeloma
-
1:29
insights into the biology of high-risk myeloma and advances being made in this space
-
2:49
defining high-risk myeloma
-
2:56
the exciting future of bispecific antibodies
-
4:26
what are bispecific antibodies?
-
4:02
an overview of bispecifics in r/r myeloma and their integration into the treatment landscape
-
1:33
sequencing and the management of adverse events when administering bispecifics for myeloma
-
1:56
bfcr4350a: a novel bispecific antibody in r/r myeloma therapy
-
1:36
identification of high-risk disease using molecular profiling by mymap